Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
Eli Lilly reported first-quarter adjusted profit that topped Wall Street's expectations. The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and ...
Core PCE Inflation Matches Estimates for AprilFri, 31 May 2024 12:48:04 GMT Euro Area Inflation Rises to 2.6%, Core CPI Jumps to 2.9%Fri, 31 May 2024 12:23:10 GMT German Retail Sales Slide by 1.2% ...
Drugmaker boosts full-year sales and profit guidance, but supply worries remain in focus Eli Lilly & Co. shares gained 4.5% Tuesday morning after the company reported first-quarter profit that ...
Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...
, opens new tab said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...